16 September 2026 editorial review · Trial
Islet transplantation into the anterior chamber of the eye: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT02846571; RECRUITING; updated 2026-03-12; enrollment 2 (ESTIMATED); results not posted.
Endpoint comparison: Absence of ocular complications (24 months after transplant); Absence of sympathetic ophthalmia (24 months after transplant); Confirmation of intraocular islet graft survival (24 months after transplant).
Sources for this record: NCT02846571 — Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye (registry); Intraocular Islet Transplant (manufacturer); Local release of rapamycin by microparticles delays islet rejection within the anterior chamber of the eye (peer-reviewed).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.